Search
Aclacinomycin 10-hydroxylase RdmB
go.drugbank.com/bio_entities/BE0002526TargetStreptomyces purpurascensIn vivo and in vitro, RdmB catalyzes the removal of the carboxylic group from the C-10 position of 15-demethoxyaclacinomycin T coupled to hydroxylation at the same C-10 position. … It could also catalyze the removal of the carboxylic group at the C-10 position of 15-demethoxy-epsilon-rhodomycin coupled to hydroxylation at the same C-10 position to yield rhodomycin B.
Polypeptides: Aclacinomycin 10-hydroxylase RdmBSynonyms: 15-demethoxy-epsilon-rhodomycin 10-hydroxylaseImmunoglobulin superfamily member 10
go.drugbank.com/bio_entities/BE0004612TargetHumansInvolved in the control of early migration of neurons expressing gonadotropin-releasing hormone (GNRH neurons) (By similarity). May be involved in the maintenance of osteochondroprogenitor cells pool (By similarity)
Polypeptides: Immunoglobulin superfamily member 10Lynestrenol
go.drugbank.com/drugs/DB12474ApprovedWithdrawnLynestrenol is a progestin and prodrug of [norethisterone].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ORGAMETRİL 5 MG TABLET, 30 ADETCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]
Products: CİMZİA 200 MG/ML S.C. ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR (2 ADET), CIMZIA 200 MGCiclesonide
go.drugbank.com/drugs/DB01410ApprovedInvestigationalCiclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Mixtures: LUXNID 2/200 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL,120 KAPSÜL, LUXNID 2/400 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL,120 KAPSÜLCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTriptorelin
go.drugbank.com/drugs/DB06825ApprovedInvestigationalVet approvedTriptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).
Synonyms: (6-D-Tryptophan)luteinizing hormone-releasing hormone, (D-Trp6)-GnRHProducts: GONAPEPTYL 0,1 MG/ML ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, DECAPEPTYL DEPOT 3,75 MG INJEKSIYONLUK SUSPANSIYON ICIN TOZ VE COZUCU, 1 ADETEthambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967. … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.
Mixtures: RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MG, RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MGCategories: MATE 1 Substrates, MATE 2 SubstratesExemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalIt irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 6-methyleneandrosta-1,4-diene-3,17-dioneEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesProducts: REVOLADE ® TABLETAS 50 MG, ROMPAG 50 MG FİLM KAPLI TABLET, 14 ADETRisdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigational[L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless … [L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription.
Categories: MATE 1 Inhibitors, Heterocyclic Compounds, 1-RingProducts: Evrysdi 0,75 mg/mL Oral Çözelti Hazırlamak İçin Toz, 80 ML, Evrysdi Powder for oral solution 0.75 mg/mL